Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pharmacodynamics in Geriatric Patients: Effects of Age01:27

Pharmacodynamics in Geriatric Patients: Effects of Age

343
Age-related pharmacokinetic changes are extensively documented, but understanding age-related pharmacodynamic alterations is relatively limited. This knowledge gap can be partly attributed to the complexity of developing appropriate measures of drug responses compared to bioanalytical methods for determining drug concentrations.Most information regarding age-related differences in human pharmacodynamics originates from cross-sectional studies. However, these studies assume that observed mean...
343
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Excretion01:18

Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Excretion

331
In geriatric patients, renal physiology undergoes significant changes, including diminished renal blood flow and a lower glomerular filtration rate (GFR), leading to alterations in medication clearance. Drugs such as aminoglycoside antibiotics, lithium, and digoxin, which rely on glomerular filtration for removal from the body, particularly impact pharmacokinetics. These drugs tend to have slower clearance rates in older adults, necessitating careful dosage considerations.Evaluation of renal...
331
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Metabolism01:18

Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Metabolism

356
Geriatric patients show significant variation in how their bodies process medications, which can change how effective and safe treatments are. The liver is the primary organ where drug metabolism occurs, involving two main types of chemical reactions: phase I and II. Phase I metabolism is driven by the cytochrome P450 enzyme system, which includes key types such as CYP3A, CYP2D6, and CYP2C9. Research indicates that while aging doesn't notably alter the levels or activity of these enzymes, it...
356
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Absorption01:22

Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Absorption

817
As individuals age, their body's physiology evolves, affecting drug pharmacokinetics. The most apparent changes occur in the gastrointestinal tract, where an increase in gastric pH, a delay in gastric emptying, and a reduction in gastrointestinal motility are observed. Remarkably, these changes do not substantially modify the absorption of orally administered drugs, particularly those absorbed via passive diffusion.Transdermal drug delivery emerges as a highly viable method for older adults due...
817
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Distribution01:00

Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Distribution

353
Drug distribution in the human body is influenced by several factors, including plasma protein concentration, body composition, blood flow, tissue-protein concentration, and tissue fluid pH. Among these, changes in plasma protein concentration and body composition due to aging significantly affect how drugs are distributed within the body. Specifically, aging is associated with a decrease in albumin levels by about 10% and an increase in α1-acid glycoprotein levels. These alterations are...
353
Drug Dosing: Geriatric Patients01:15

Drug Dosing: Geriatric Patients

374
Elderly individuals encompass a diverse population with varying degrees of age-related physiological changes. Defining the elderly presents challenges, as the geriatric population is often arbitrarily categorized as individuals older than 65. However, many individuals in this group lead active and healthy lives, with an increasing number surpassing 85 years and falling into the older elderly category. Physiological changes associated with aging impact performance capacity and homeostatic...
374

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Online group exercise for people with Parkinson's disease: rehabilitation and fitness professionals' experiences to inform physiotherapy practice and service delivery - a qualitative interview study.

Physiotherapy theory and practice·2026
Same author

Impact of Maternal COVID-19 Infection Versus Vaccination on Mucosal Immunity in Breastmilk.

Journal of clinical medicine·2026
Same author

Retention and Structural Inequities in Clinical Research: Insights from a Breastfeeding Intervention Study.

Journal of health care for the poor and underserved·2026
Same author

Foundations of Gerophysics.

Aging·2026
Same author

Climate informed precision health.

Frontiers in public health·2026
Same author

Inferring Gene Regulatory Network Architecture Underlying Complex Traits: An Integrative Analysis of Mutant Lifespan and Gene Expression Profiles Identifies Master Regulators and Key Functional Modules for Yeast Aging.

Aging cell·2026

Related Experiment Video

Updated: Apr 17, 2026

Improving Strength, Power, Muscle Aerobic Capacity, and Glucose Tolerance through Short-term Progressive Strength Training Among Elderly People
12:59

Improving Strength, Power, Muscle Aerobic Capacity, and Glucose Tolerance through Short-term Progressive Strength Training Among Elderly People

Published on: July 5, 2017

13.4K

Exercise and Weekly Sirolimus (Rapamycin) in Older Adults: RAPA-EX-01 Randomised, Double-Blind, Placebo-Controlled

Brad Stanfield1,2, Brian Leroux3, Matt Kaeberlein3,4

  • 1Royal New Zealand College of General Practitioners, Wellington, New Zealand.

Journal of Cachexia, Sarcopenia and Muscle
|April 15, 2026
PubMed
Summary

This study found that weekly sirolimus (rapamycin) did not improve exercise gains in older adults and may have reduced them, increasing adverse events. Further research is needed to explore optimal dosing for potential benefits.

Keywords:
Geroscienceagingexercise trainingmTORmTORC1 inhibitionphysical functionrandomised controlled trialrapamycinsarcopeniasirolimus

More Related Videos

A Semi-Quantitative Drug Affinity Responsive Target Stability DARTS assay for studying Rapamycin/mTOR interaction
05:28

A Semi-Quantitative Drug Affinity Responsive Target Stability DARTS assay for studying Rapamycin/mTOR interaction

Published on: August 27, 2019

18.0K
Author Spotlight: Advancing Diabetes Research with Static Exercise Training in Mice
03:17

Author Spotlight: Advancing Diabetes Research with Static Exercise Training in Mice

Published on: March 29, 2024

1.2K

Related Experiment Videos

Last Updated: Apr 17, 2026

Improving Strength, Power, Muscle Aerobic Capacity, and Glucose Tolerance through Short-term Progressive Strength Training Among Elderly People
12:59

Improving Strength, Power, Muscle Aerobic Capacity, and Glucose Tolerance through Short-term Progressive Strength Training Among Elderly People

Published on: July 5, 2017

13.4K
A Semi-Quantitative Drug Affinity Responsive Target Stability DARTS assay for studying Rapamycin/mTOR interaction
05:28

A Semi-Quantitative Drug Affinity Responsive Target Stability DARTS assay for studying Rapamycin/mTOR interaction

Published on: August 27, 2019

18.0K
Author Spotlight: Advancing Diabetes Research with Static Exercise Training in Mice
03:17

Author Spotlight: Advancing Diabetes Research with Static Exercise Training in Mice

Published on: March 29, 2024

1.2K

Area of Science:

  • Gerontology
  • Exercise Physiology
  • Pharmacology

Background:

  • Preclinical studies suggest mTORC1 modulation via exercise may enhance adaptation.
  • The 'cycling hypothesis' proposes alternating mTORC1 activation/inhibition for exercise benefits.
  • Translational evidence in older adults remains unexplored.

Purpose of the Study:

  • To investigate if weekly sirolimus (rapamycin) enhances functional gains from home-based exercise in older adults.
  • To assess the safety and efficacy of this intervention in a sedentary older population.
  • To explore the 'cycling hypothesis' in the context of aging and exercise.

Main Methods:

  • Randomized, double-blind, placebo-controlled trial with 40 sedentary adults (65-85 years).
  • Intervention: 6mg sirolimus or placebo weekly for 13 weeks, alongside a home exercise program (resistance and endurance).
  • Primary outcome: change in 30-s chair-stand repetitions; secondary outcomes: grip strength, 6-min walk, SF-36, epigenetic age.

Main Results:

  • Both groups improved chair-stand performance; however, sensitivity analyses (complete-case and per-protocol) showed sirolimus attenuated gains (p=0.045 and p=0.007).
  • Secondary functional outcomes and quality-of-life scores favored placebo but were not statistically significant.
  • Sirolimus group experienced a higher burden of adverse events, including one serious infection.

Conclusions:

  • Once-weekly sirolimus (rapamycin) did not enhance, and potentially attenuated, short-term functional improvements from exercise in older adults.
  • The regimen increased adverse events, suggesting a potentially unfavorable benefit-risk profile.
  • Future trials require adjusted dosing or duration to determine if mTORC1 modulation can be beneficial.